Helius Medical Technologies, Inc. (HSDT) Tops Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Helius Medical Technologies, Inc. Reports Second Quarter 2022 Financial Results
August 15, 2022 4:05 PM EDT-- Net proceeds from August 2022 financing and cash on hand expected to fund operations through 2023 --
-- Company to host call at 4:30pm today --
NEWTOWN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended June 30, 2022.
Second Quarter and Recent Business Updates
Fulfilled first U.S. prescriptions of PoNS Therapy for use in multiple... More
